Meta-analysis of 5 RCTs (975 adults) having myeloablative allo-HSCT: busulfan/fludarabine was associated with lower 1-year non-relapse mortality than busulfan/cyclophosphamide (RR 0.49; 2 trials) and fewer grade 3-5 events, with no difference in overall mortality.
Meta-analysisn = 975
Shimada et al. Comparison of Myeloablative Busulfan/Cyclophosphamide and Busulfan/Fludarabine for Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis